Brentuximab vedotin improves progression-free survival in Hodgkin’s lymphoma patients [AETHERA trial]
1. In this phase 3 randomized controlled clinical trial, brentuximab vedotin significantly improved progression-free survival in Hodgkin’s lymphoma patients at ...